helpline 01494 601 400

Dravet syndrome

Why NICE is right to be cautious about recommending medicinal cannabis for two childhood epilepsy syndromes

Why NICE is right to be cautious about recommending medicinal cannabis for two childhood epilepsy syndromes. Our medical director, Professor Ley Sander writes.

Phase 3 clinical trial announced for Dravet Syndrome drug

The second Phase 3 clinical trial is to begin for ZX008, a branded version of low-dose fenfluramine, designed as an adjunctive treatment of seizures in children with Dravet syndrome.

GW Pharmaceuticals begins phase 3 Epidiolex study in tuberous sclerosis complex

GW Pharmaceuticals has announced the start of a Phase 3 clinical trial of Epidiolex® (a cannabidiol-based medication) as an adjunctive therapy for the treatment of epileptic seizures in the rare genetic disorder tuberous sclerosis complex (TSC).

Young girl with epilepsy goes shopping with Duchess of Cambridge

Eleven-year-old girl with a rare form of childhood epilepsy steals show when she takes the Duchess of Cambridge on an impromptu tour of a new charity shop.

Subscribe to RSS - Dravet syndrome